Language selection

Search

Notice of submission from Pioneer Hi-Bred Canada Company for novel food, livestock feed and environmental safety approval for commercial planting purposes of a plant genetically modified for herbicide tolerance and enhanced grain yield potential

June 6, 2019

Background

The CFIA and Health Canada have received a submission from Pioneer Hi-Bred Canada Company seeking an environmental safety approval for commercial planting purposes and livestock feed and food use of a maize line designated as DP202216, which has been genetically modified to exhibit herbicide tolerance and enhanced grain yield potential. The DP202216 maize was genetically modified to increase and extend expression of the zmm28 gene relative to the native zmm28 gene expression. Both the introduced and native zmm28 genes encode the ZMM28 protein, a MADS-box transcription factor. The increased and extended expression of the ZMM28 protein results in enhanced grain yield potential. The DP202216 maize also contains the PAT (phosphinothricin acetyltransferase) protein, which confers tolerance to the herbicidal active ingredient glufosinate ammonium at current labeled rates. The PAT protein present in DP202216 maize is identical to the corresponding protein found in a number of approved events across several different crops that are currently in commercial use.

The submission received is in accordance with CFIA guidelines for assessment of plants with novel traits for unconfined release, CFIA guidelines for assessment of novel feeds from plants with novel traits, and Health Canada guidelines for assessment of novel foods.

Summary of the submission package

Updated scientific information may be added to this submission by the developer at a later date, or CFIA and/or Health Canada may request further information from the developer.

Description of the host plant

Please refer to Biology Document BIO 1994-11: The Biology of Zea mays (L.) (Maize).

Description of the modification

Corn line DP202216 was developed through the use of recombinant DNA technology. In order to assess the modification process, the following has been submitted:

Inheritance and stability of the introduced trait

In order to assess the inheritance and stability of the genetic modification the following has been submitted:

Description of the novel traits

In order to characterize the novel proteins produced in the plant, the following has been submitted:

Absence of toxicity of the novel gene products

To support the absence of toxicity of the expressed genetic components on non-target species, humans and animals, the following have been submitted or previously submitted, reviewed, or published:

Nutritional evaluation of the novel plant

In order to assess nutritional aspects of the novel plant the following has been submitted:

Allergenicity considerations

In order to assess allergenicity of the expressed genetic components the following has been submitted:

Evaluation of the environmental impact of the novel plant

In order to assess the environmental impact of the novel plant the following has been submitted:

For more information on this product, please contact:

Pioneer Hi-Bred Canada Company
7398 Queen's Line,
Chatham, ON, N7M 5L1

CFIA and Health Canada, including their employees, are not responsible for the content of this Notice of Submission as submitted by the Applicant. All Notices of Submission are the responsibility of the Applicant submitting them and the Applicant does so at its own risk. Submission of this Notice of Submission and its subsequent posting by CFIA on its website does not in any way whatsoever constitute acceptance, approval or certification by CFIA or Health Canada of the Plant with Novel Trait(s) subject of the Notice of Submission and CFIA and Health Canada reserve all their rights under all the pertinent legislation that may be applicable. The CFIA and Health Canada in no way whatsoever waives any of their rights under any of the legislation they enforce or administer by way of the CFIA posting this Notice of Submission.

The Applicant is not obliged to provide any information. The Applicant submits information that it chooses to submit. The information that the Applicant voluntarily provides on this Notice of Submission is collected by the CFIA and Health Canada for the purpose of sharing information with the public. Personal Information will be protected under the provisions of the Privacy Act, and will be stored in Personal Information Bank CFIA PPU 125. Information, including personal information, may be accessible or protected as required under the provisions of the Access to Information Act.

Public communications

Provision of the information requested on this form is voluntary. The personal information you include in an inquiry may be used to prepare a reply. The personal information is collected pursuant to the Canadian Food Inspection Agency Act. Such information may be used for statistical, evaluation and reporting purposes. The information may be shared with programs and activities of the Canadian Food Inspection Agency should your inquiry pertain to a specific program or activity of the agency.

The transmission of this information is not secure so sensitive personal information, such as your Social Insurance Number, should not be included in your message.

Submit Comment

If after reading this statement, you prefer not to submit your inquiry via the Internet, you may send your comments to Canadian Food Inspection Agency via postal mail or email:

Canadian Food Inspection Agency
Plant Biosafety Office
59 Camelot Drive,
Ottawa, ON,
K1A 0Y9

Email: cfia.infobiotech-infobiotech.acia@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: